# Nuvectis Pharma Inc. (NVCT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $24.49, market value $799 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Nuvectis Pharma Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 72.0×**. The shares trade at 72.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -143.6%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -18.9%**. Earnings per share fell 18.9%.

## Financial health
- **Current ratio: 2.38** (quick 2.38). Current assets cover the next year's liabilities 2.38 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Nuvectis Pharma Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Nuvectis Pharma Inc.; the consensus is strong_buy, with an average price target of $35.40 (+45% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 275.6%** (YTD 224.4%, 3-mo 156.7%). The shares are up 275.6% over twelve months including dividends.
- **From 52-week high: -16.3%** (341.3% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 62**. An RSI of 62 is neutral.
- **Beta (1 yr): 1.03** (volatility 83%). Beta of 1.03 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NVCT · Page: https://foliofundamentals.com/stocks/nvct

Not investment advice.